The renoprotective effect of once-weekly GLP-1 receptor agonist dulaglutide on progression of nephropathy in Japanese patients with type 2 diabetes and moderate to severe chronic kidney disease (JDDM67).
Ken-Ichi TsuchidaShinji TanedaIsao YokotaKazufumi OkadaYoshio KuriharaHiroki YokoyamaMasahiro IwamotoKatsuya YamazakiYasushi IshigakiNaoki MandaHiroshi Maegawanull nullPublished in: Journal of diabetes investigation (2022)
Dulaglutide slowed the eGFR decline in patients with type 2 diabetes and CKD stage 3 to 4.